FINHUB Insights

MCK · Q2 FY26 · Jul 1 – Sep 30, 2025

McKesson Q2 FY26: where the revenue came from and where it went

McKesson Q2 FY26: revenue $103.2B (+10% year over year). Net profit $1.1B. Largest cohort North American Pharmaceutical $86.5B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jul 1 – Sep 30, 2025
Reported
Nov 6, 2025 10-Q
Sankey diagram of McKesson's income statement for Q2 FY26: revenue of $103.2 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$103.2B +10% year over year
Gross profit$3.5B 3% margin
Operating profit$1.4B 1% margin
Net profit$1.1B 1% margin

The numbers

All figures in billions of U.S. dollars, for Q2 FY26 (period ends Sep 30, 2025).
ItemValueShare of revenueYear over year
Revenue 103.2 100% +10%
North American Pharmaceutical 86.5 84%
Oncology & Multispecialty 12 12%
Medical-Surgical Solutions 2.9 3% +0%
Prescription Technology 1.4 1% +9%
Other 0.3 0%
Cost of revenue−99.697%
Gross profit3.53% margin+0pp
SG&A−2.12%−1pp
Operating profit1.41% margin+1pp
Tax−0.2
Interest & other costs−0.1
Net profit1.11%+1pp
Filing on EDGAR More quarters of MCK

Source of the numbers: tables in the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters